<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354626</url>
  </required_header>
  <id_info>
    <org_study_id>LiF-Pro</org_study_id>
    <nct_id>NCT01354626</nct_id>
  </id_info>
  <brief_title>Dietary Protein and Hepatic Fat Accumulation</brief_title>
  <acronym>LiF-Pro</acronym>
  <official_title>Influence of Increasing Dietary Protein on Hepatic Fat Accumulation and Postprandial Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the potential beneficial effect of increasing&#xD;
      protein in the diet in order to decrease hepatic lipid accumulation on a high-fat diet.&#xD;
&#xD;
      The investigators hypothesize that increasing protein in a high-fat diet suppresses lipid&#xD;
      accumulation in the liver, and that changes in (hepatic) fat handling underlie this reduced&#xD;
      lipid accumulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hepatic fat accumulation</measure>
    <time_frame>baseline, 2 weeks, 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of liver function/hepatic steatosis</measure>
    <time_frame>baseline, 2 weeks, 4 weeks</time_frame>
    <description>Biomarkers of liver function/hepatic steatosis: ALT, AST, C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating cytokines</measure>
    <time_frame>baseline, 2 weeks, 4 weeks</time_frame>
    <description>adiponectin, TNF-Î±</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial lipid metabolism</measure>
    <time_frame>2 weeks, 4 weeks</time_frame>
    <description>Postprandial lipid metabolism will be assessed by means of a meal challenge with the use of stable isotope tracer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose homeostasis</measure>
    <time_frame>baseline, 2 weeks, 4 weeks</time_frame>
    <description>Glucose homeostasis will be assessed with the homeostatic model assessment (HOMA) index in fasting blood samples. In addition dynamic indexes will be determined from the meal challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue gene expression</measure>
    <time_frame>2 weeks, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood mononuclear cells gene expression (PBMC's).</measure>
    <time_frame>baseline, 2 weeks, 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hepatic Fat Accumulation</condition>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>High fat diets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-fat-Low-protein or High-fat-high-protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low-protein-low-fat (according to healthy eating guidelines)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dietary protein</intervention_name>
    <description>in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided</description>
    <arm_group_label>High fat diets</arm_group_label>
    <other_name>diet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low-protein</intervention_name>
    <description>The control group will get a diet which is according to healthy eating guidelines.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  body mass index (BMI) 18-25 kg/ m2;&#xD;
&#xD;
          -  stable dietary habits;&#xD;
&#xD;
          -  physical activity levels.&#xD;
&#xD;
          -  caucasian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to comply with study procedures;&#xD;
&#xD;
          -  not caucasian&#xD;
&#xD;
          -  Unstable body weight (weight gain or loss &gt; 3 kg in the past three months);&#xD;
&#xD;
          -  Moderate intense physical activity (exercise) for more than 4 hours/week;&#xD;
&#xD;
          -  (Chronic) disease which might influence the study outcomes e.g. diabetes mellitus or&#xD;
             any other endocrine disorder, active cardiovascular disease, hepatic disease, renal&#xD;
             disease, cancer;&#xD;
&#xD;
          -  Family history of diabetes mellitus;&#xD;
&#xD;
          -  Use of medication, except incidental use of paracetamol;&#xD;
&#xD;
          -  Abuse of drugs;&#xD;
&#xD;
          -  Alcohol consumption of more than 14 glasses per week;&#xD;
&#xD;
          -  Participation in another biomedical study within 1 months prior to the first screening&#xD;
             visit;&#xD;
&#xD;
          -  Contraindications to MRI scanning. These contraindications include patients with one&#xD;
             of the following conditions:&#xD;
&#xD;
          -  Claustrophobia;&#xD;
&#xD;
          -  Central nervous system aneurysm clips;&#xD;
&#xD;
          -  Implanted neural stimulator;&#xD;
&#xD;
          -  Implanted cardiac pacemaker or defibrillator;&#xD;
&#xD;
          -  Cochlear implant;&#xD;
&#xD;
          -  Ocular foreign body (e.g. metal shavings);&#xD;
&#xD;
          -  Insulin pump;&#xD;
&#xD;
          -  Metal shrapnel or bullet;&#xD;
&#xD;
          -  Or metal containing corpora aliena in the eye of brains.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wageningen University, Division of Human Nutrition</name>
      <address>
        <city>Wageningen</city>
        <state>Gelderland</state>
        <zip>6703 HD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic fat accumulation</keyword>
  <keyword>Dietary protein</keyword>
  <keyword>NAFLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

